dc.contributor.author | Evans, C | |
dc.contributor.author | Jones, CE | |
dc.contributor.author | Prendergast, AJ | |
dc.date.accessioned | 2019-04-24T11:12:29Z | |
dc.date.available | 2016-01-21 | |
dc.date.available | 2019-04-24T11:12:29Z | |
dc.date.issued | 2016-03-31 | |
dc.identifier.citation | Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect Dis. 2016;16:e92–e107. | en_US |
dc.identifier.issn | 1473-3099 | |
dc.identifier.uri | http://openaccess.sgul.ac.uk/107658/ | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/57000 | |
dc.description.abstract | The number of infants infected with HIV is declining with the rise in interventions for the elimination of paediatric HIV infection, but the number of uninfected infants exposed to HIV through their HIV-infected mothers is increasing. Interest in the health outcomes of HIV-exposed, uninfected infants has grown in the past decade, with several studies suggesting that these infants have increased mortality rates, increased infectious morbidity, and impaired growth compared with HIV-unexposed infants. However, heterogeneous results might reflect the inherent challenges in studies of HIV-exposed, uninfected infants, which need large populations with appropriate, contemporaneous comparison groups and repeated HIV testing throughout the period of breastfeeding. We review the effects of HIV exposure on mortality, morbidity, and growth, discuss the immunological abnormalities identified so far, and provide an overview of interventions that could be effective in this susceptible population. As the number of infants infected with HIV declines, the health needs of HIV-exposed, uninfected infants should be prioritised further, to ensure that post-2015 Sustainable Development Goals are achieved. | en_US |
dc.description.sponsorship | CE is funded by the National Institute for Health Research. AJP is funded by the Wellcome Trust (108065/Z/15/Z). | en_US |
dc.format.extent | e92 - e107 | |
dc.language | eng | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Lancet Infect Dis | |
dc.rights | CC-NC ND | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | Africa | en_US |
dc.subject | Antiviral Agents | en_US |
dc.subject | Female | en_US |
dc.subject | HIV Infections | en_US |
dc.subject | Humans | en_US |
dc.subject | Immune System | en_US |
dc.subject | Infant | en_US |
dc.subject | Infant, Newborn | en_US |
dc.subject | Infectious Disease Transmission, Vertical | en_US |
dc.subject | Pregnancy | en_US |
dc.subject | Pregnancy Complications, Infectious | en_US |
dc.subject | Risk Factors | en_US |
dc.title | HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. | en_US |
dc.type | Article | en_US |
dc.rights.holder | 2016 Elsevier Ltd. | |
dc.identifier.doi | 10.1016/S1473-3099(16)00055-4 | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/27049574 | en_US |
pubs.issue | 6 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 16 | en_US |
dcterms.dateAccepted | 2016-01-21 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |